A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06755347 After Single Ascending Intravenous Infusions To Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2019
At a glance
- Drugs PF-06755347 (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 14 Jan 2019 Status changed from suspended to recruiting.
- 14 Jan 2019 Planned End Date changed from 13 Nov 2019 to 12 May 2021.
- 14 Jan 2019 Planned primary completion date changed from 13 Nov 2019 to 12 May 2021.